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etters to the Editor – Brief papers about basic research or clinical experiences
apturing  the  diagnosis  of  chronic kidney  disease  in  the
lectronic medical  record  and  its  inﬂuence  on  therapeutic
anagementegistro  del  diagnóstico  de  insuﬁciencia  renal  crónica  en  la  historia
n  línica  electrónica  y  su  inﬂuencia  e
ear Editor,
hronic kidney disease (CKD) affects 9% of the adult pop-
lation in Spain.1,2 The majority of patients with CKD are
anaged by primary care physicians,3–6 and early detec-
ion is essential for adopting the measures required to
low its progression.7,8 At the primary care clinics, the
hysician includes in the electronic medical record the
iagnosis of chronic kidney disease (CKD) manually when
he estimated glomerular ﬁltration rate (GFR) is lower than
0 ml/min/1.73 m2. The objective of the study is to deter-
ine, in patients with a GFR < 60 ml/min/1.73 m2, whether
ocumenting a diagnosis of CKD in the record encompasses
ifferent attitudes with respect to the prevention and treat-
ent of CKD.
The study was performed in the 16 primary care teams
rom the Muntanya Primary Care Service (SAP) in Barcelona,
elonging to the Catalan Health Institute (ICS), where
12,321 adult patients were covered for health care in 2012.
atients with a minimum of 2 estimated glomerular ﬁltra-
ion rates (eGFRs) using the CKD-EPI formula lower than
0 ml/min/1.73 m2 in 2012 were enrolled. We  identiﬁed two
roups of patient depending of whether to diagnosis of CKD
ad been recorded in the medical history. A between-groups
omparison was performed using the chi-squared test for
ualitative variables and Student’s t test for quantitative vari-
bles. A level of statistical signiﬁcance of 5% (p ≤ 0.05) was
ccepted.
In 2331 patients, at least 2 eGFR measurements
60 ml/min/1.73 m2 were recorded. The diagnosis of CKD
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had been recorded in 1344 patients (57%), but not in 987
patients (43%). Table 1 summarises the patients’ charac-
teristics. The patients with a recorded diagnosis of CKD
had a lower eGFR and greater albuminuria. The proportion
of diabetics was similar in the two groups. Body weight,
LDL cholesterol and glycated haemoglobin in patients with
diabetes were lower in the group of patients with a diagnosis
of CKD. Table 2 summarises the treatment in both groups.
The use of renin–angiotensin system inhibitors was similar
in the both groups. By contrast, the use of non-steroidal anti-
inﬂammatory drugs was lower in patients with the diagnosis
of CKD. In diabetic patients the use of metformin and sulpho-
nylureas was also lower in the group with a diagnosis of CKD.
The main observation of the present study is that a diagno-
sis of CKD is made late and that the diagnosis is not shown in
the medical history of approximately 40% of patients with an
eGFR < 60 ml/min/1.73 m2. Despite the greater severity of kid-
ney disease, patients with a diagnosis of CKD recorded had less
overweight and better control of LDL cholesterol and glycated
haemoglobin (in diabetic patients). The use of non-steroidal
anti-inﬂammatory drugs was lower in the group of patients
with a diagnosis of CKD. Metformin and sulphonylureas were
used less often in diabetic patients with a diagnosis of CKD.
Taken together, these results suggest that a diagnosis of CKD is
associated with a more  proactive attitude aimed at decreasing
risk factors for cardiovascular problems and for progression ofndez-Liz E, Cossio Y, Serón D, et al. Registro del diagnóstico de
cia en el manejo terapéutico. Nefrología. 2016;36:315–317.
kidney disease and also with greater prevention of acute renal
failure. These ﬁndings raise the question of whether automat-
ically including a diagnosis of CKD in the medical history of
patients with an eGFR < 60 ml/min/1.73 m2 might foster a more
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Table 1 – Sociodemographic data and mean baseline values.
Group Without a diagnosis With a diagnosis p
N 987 1344
Age (years) (SD) 78.09  (8.74) 79.27 (8.74) <0.001
Women (n, %) 647  (65.6) 770  (57.3) <0.001
SBP (mmHg) (SD) 132.58 (19.94) 133.62 (19.47) NS
DBP (mmHg) (SD) 71.58 (12.16) 71.33 (10.94) NS
Malb (mg/g) (SD) 24.68 (58.59) 41.02 (10.88) <0.001
Creatinine (mg/dl) (SD) 1.21 (0.32) 1.62 (3.50) <0.001
GFR, ml/min/1.73 m2 (SD) 48.90 (7.99) 41.02 (10.88) <0.001
Haemoglobin (g/dl) (SD) 12.48 (1.73) 12.44 (3.23) NS
Diabetes (n, %) 496 (50.3) 641 (47.7) NS
HbA1c (%) (in DM) (SD) 7.6 (3.11) 7.3 (1.28) 0.035
BMI (kg/m2) 30.16 (5.76) 29.46 (4.91) 0.024
LDL-C (mg/dl) (SD) 110 (34.88) 105 (34.64) 0.004
No. of visitsa (2012) (SD) 18.07 (17.75) 18.72 (17.42) NS
Referralsb (n, %) 26 (2.6) 123 (9.2) <0.001
DM, diabetes mellitus; GFR, glomerular ﬁltration rate; HbA1c, glycated haemoglobin; BMI, body mass index; LDL-C, LDL cholesterol; Malb,
microalbuminuria; NS, p > 0.05; DBP, diastolic blood pressure; SBP, systolic blood pressure.
a Any visit to the site for any reason has been counted.
b Referrals to the Nephrology Department of the referral hospital.
Table 2 – Treatment differences according to group.
Group Without a diagnosis (n, %) With a diagnosis (n, %) p
Total number of cases 987 1344
ACE inhibitors 393 (39.9) 505 (37.6) NS
AIIRAs 373 (37.8) 550 (40.9) NS
ACE inhibitors + AIIRAs 5 (0.5) 4 (0.3) NS
Aliskiren 4 (0.4) 3 (0.2) NS
NSAIDs 312 (31.6) 345 (25.7) 0.002
Total diabetic patients 497 642
Diab:metformin 186 (37.4) 167 (26) <0.001
Diab:sulphonylureas 77 (15.5) 74 (11.5) 0.05
NSAIDs, non-steroidal anti-inﬂammatory drugs; AIIRAs, angiotensin II receptor antagonists; Diab, diabetic; ACE inhibitors, angiotensin con-
rverting enzyme inhibitors; NS, p > 0.05.
Bold values represent the number of patients.
proactive attitude in the treatment of these patients.9,10 How-
ever, these results should be interpreted with caution since
this is a retrospective study and therefore does not allow
causal relationships to be established. Conforming or refut-
ing this hypothesis would require a prospective randomised
study.
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